Insider · CIK 0002109299
Narinder Pal Bhalla
officer
Files at LXEO (Lexeo Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | LXEO Lexeo Therapeutics, Inc. | AGrant or award Common Stock | +2,714 | $3.58 | $9,713 | 84,908 | 15 d ago |
| Sep 24, 2026 | LXEO Lexeo Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +54,750 | $0.00 | $0 | 54,750 | 15 d ago |
| Feb 13, 2026 | LXEO Lexeo Therapeutics, Inc. | AGrant or award Common Stock | +49,500 | $0.00 | $0 | 49,500 | Feb 17, 2026 |
| Feb 13, 2026 | LXEO Lexeo Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +297,000 | $0.00 | $0 | 297,000 | Feb 17, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.